Patent for the treatment of chronic bronchitis is granted in Europe
The European Patent Office EPO has announced that it approves PharmaLundensis patent application “Activated carbon comprising an adsorbed iodide salt in a method for treating chronic bronchitis WO2014084763“. The patent is valid until 2032 with the option of an additional 5 years extension.
Patent for this project has also been approved in Japan and is pending in China and South Korea.
CEO Dr Staffan Skogvall: PharmaLundensen’s patent portfolio is developing very well. Recently, the first national patent for the COPD treatment Iodocarb comp was granted and now it is the patent that protects the treatment against chronic bronchitis that is approved on the company’s main market in Europe. I am pleased that the patent authorities understand and approve our innovative products!